trending Market Intelligence /marketintelligence/en/news-insights/trending/HkjlpWjPKtQqyUMGIgG2CA2 content esgSubNav
In This List

ImmunoGen prices common stock offering

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


ImmunoGen prices common stock offering

ImmunoGen Inc. priced an underwritten public offering of 14.5 million common shares at $6.50 apiece.

The company expects gross proceeds of about $94.3 million.

The company granted underwriters a 30-day option to buy up to an additional 2,175,000 common shares at the offering price.

The offering is expected to close by Oct. 11, subject to customary closing conditions.

ImmunoGen plans to use net proceeds to help fund its operations, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the offering, with Canaccord Genuity as sole co-manager.